Interní Med. 2009; 11(1): 13-16

Vitamin D - an essential component of osteoporosis treatment

MUDr. Jiří Jenšovský
Osteocentrum, ÚVN Praha

Pandemic of osteoporosis is becoming more and more evident with aging of population and increasing longevity. A very persuading

numbers about fractures, mainly of femoral neck, are alarming and are becoming a population problem. The basic preventive measure

is an effort to reach optimal and as great as possible peak bone mass that is determined genetically and influenced by a number of modifiable

external factors. The condition for a successful development, skeletal maintenance and osteopenia or osteoporosis treatment

effect is sufficient saturation with calcium and vitamin D in every age.

Besides pandemic of osteoporosis aging population worldwide faces subclinical deficit of vitamin D that leads to acceleration of age

related increase in secretion of parathormon and is one of principal mechanisms of bone mass loss in higher age decades – involutional

osteoporosis. Subclinical vitamin D deficit manifests also by sarcopenia, muscle weakness, instability and functional disorders increasing

the risk of falls. This state is reversible after saturation with vitamin D. All clinical studies concerning antiresorbtive therapy are performed

always with concomitant saturation with calcium and vitamin D; currently there are combined medications with biphosphonate

and vitamin D in one pill. Besides supplementation with a regular vitamin D we have now also a pharmacotherapeutic intervention with

a more active metabolite alfacalcidole, that nesides effect on skeleton shows also a very positive effect on muscular system and can

prevent osteoporosis fractures by limiting a number of falls.

Keywords: Key words: vitamin D, osteoporosis, osteoporotic fractures myopathy, alfacalcidiol.

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jenšovský J. Vitamin D - an essential component of osteoporosis treatment. Interní Med. 2009;11(1):13-16.
Download citation

References

  1. Sherman S. Human aging at the milenium. In, ,The aging skeleton" Academic Press, San Diego, 1999: 11-17. Go to original source...
  2. Broulík P. Osteoporóza. Praha, Maxdorf 1999: 66-67.
  3. Singer K, Edmonston S, Day R, et al. Prediction of thoracic and lumbar vertebral body compressive strength: correlations with bone mineral density and vertebral region. Bone, 1995; 17: 167-174. Go to original source... Go to PubMed...
  4. Beck T, Ruff C, Scott W, et al. Sex differences in geometry of the femoral neck with aging. Calcif Tissue Int, 1992; 50: 24-29. Go to original source... Go to PubMed...
  5. Cooper C, Atkinson EJ, O Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: A population-based study in Rochester. J Bone Miner Res, 1992; 7: 221-227. Go to original source... Go to PubMed...
  6. Bachrach LK. Calcium and peak bone mass: how much is needed and when. Am J Clin Nutr, 2005; 81: 175-188. Go to original source...
  7. Heaney RP, Recker RR, Stegman MR, et al. Calcium absorption in women: relationships to calcium intake, estrogen status and age. J Bone Miner Res, 1989; 4: 469-475. Go to original source... Go to PubMed...
  8. Shea B, Wells G, Cranney A, et al. Metaanalysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev, 2002; 552-559. Go to original source... Go to PubMed...
  9. Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D and solar ultraviolet radiation. Lancet, 1989; 2: 1104-1105. Go to original source... Go to PubMed...
  10. Holick MF. Vitamin D: new horizons for 21st century. Am J Clin Nutr, 1994; 619-630. Go to original source... Go to PubMed...
  11. Passeri G, Pini G, Troiano L, et al. Low vitamin D status, high bone turnover and bone fractures in centenarians. J Clin Endocrinol Metab, 2003; 88: 5109-5115. Go to original source... Go to PubMed...
  12. Malaban A, Veronikis IE, Holick MF. Redefining vitamin D deficiency. Lancet, 1998; 351: 805-806. Go to original source... Go to PubMed...
  13. Young A, Edwards RHT, Jones DA, et al. Quadriceps muscle strength and fibre size during the treatment of osteomalacia. In: Mechanical factors and skeleton (IAF Stokes and J Stokes eds) 1982: 137-145.
  14. Visser M, Deeg DJ, Lips P. Low vitamin D status and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass/sarcopenia: The longitudinal aging study Amsterdam. J Clin Endocrinol Metab, 2003; 88: 5766-5772. Go to original source... Go to PubMed...
  15. Grundberg E, Brandstrom H, Ribom EL, et al. Genetic variation in the human vitamin D receptor is associated with muscle strength, fat mass and body weight in Swedish women. Europ J Endocrinol, 2004; 150: 323-328. Go to original source... Go to PubMed...
  16. Rubin J, Rubin H, Rubin C. Constraints of experimental paradigms used to model the aging skeleton. In The aging skeleton, Academic Press, San Diego, 1999; 27-36. Go to original source...
  17. Whitelaw GP, Abramowitz AJ, Kavookjian H, Holick MF. Fractures and vitamin D deficiency in elderly. Complications Ortho, 1991; 6: 70-80.
  18. Webb AR, Pilbeam C, Hanafin N, Holick MF. An evaluation of the relative contributions of exposure to sunlight and diet on the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr, 1990; 51: 1075-1081. Go to original source... Go to PubMed...
  19. Ledger GA, Burritt MF, Kao PC et al: Abnormalities of PTH secretion in elderly women are reversible by short term therapy with 1,25 hydroxyvitamin D. J Clin Endocrinol Metab, 1994, 79: 211-216. Go to original source...
  20. Riggs BL, Melton L. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med, 1983: 899-901. Go to original source... Go to PubMed...
  21. Recker R, Lips P, Felsenberg D et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controled trial. Curr Med Res Opin, 2006, 22: 1745-1755. Go to original source... Go to PubMed...
  22. Lau K H W, Baylink DJ. Treatment of 1,25 OH2 D3 deficiency/resistence with D hormone and analogs. Osteologie, 2001, 10: 28-39.
  23. Schacht E. Rationale for the treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid induced osteoporosis with alfacalcidol. Calcif Tissue Int, 1999, 65: 317-327. Go to original source... Go to PubMed...
  24. ShiraishiA, Higashi S, Ohkawa H et al. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int, 1999, 65: 311-316. Go to original source... Go to PubMed...
  25. Sorensen O H, Lund B I, Saltin B et al. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha hydroxycholecalciferol and calcium. Clin Sci, 1979, 56: 157-161. Go to original source... Go to PubMed...
  26. Papadimitropoulos E, Wells G, Shea B et al. The osteoporosis metodology group and the osteoporosis research advisory group: meta analysis of the efficacy of vitamin D treatment in the preventing osteoporosis in postmenopausal women.Endocrine Reviews, 2002, 23: 560-569. Go to original source... Go to PubMed...
  27. American College of Rheumatology ad hoc comittee on glucocorticoid induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheumatism, 2001, 44: 1496-1503.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.